Inverse association of long-acting natriuretic peptide with metabolic syndrome in congestive heart failure patients

Diabetology and Metabolic Syndrome

Volumn 5, Issue 1, 2013, Pages

  Wang, Ji Hung ^a,b   Lee, Chung Jen ^c   Hsieh, Jen Che ^b   Chen, Yu Chih ^b   Hsu, Bang Gee ^a,b  

^a TZU CHI UNIVERSITY   (Taiwan)

^b BUDDHIST TZU CHI GENERAL HOSPITAL   (Taiwan)

^c TZU CHI COLLEGE OF TECHNOLOGY   (Taiwan)

Author keywords

Congestive heart failure; Homeostasis model assessment of insulin resistance; Long acting natriuretic peptide; Metabolic syndrome

Indexed keywords

LONG ACTING NATRIURETIC PEPTIDE; NATRIURETIC FACTOR; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; BODY WEIGHT; CLINICAL ASSESSMENT TOOL; CONGESTIVE HEART FAILURE; DISEASE ASSOCIATION; FEMALE; HOMEOSTASIS MODEL ASSESSMENT OF INSULIN RESISTANCE; HORMONE BLOOD LEVEL; HUMAN; LONG ACTING NATRIURETIC PEPTIDE BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; PATHOPHYSIOLOGY; PRIORITY JOURNAL;

EID: 84875867518     PISSN: None     EISSN: 17585996     Source Type: Journal    
DOI: 10.1186/1758-5996-5-19     Document Type: Article

References (38)

1. Which of the cardiac natriuretic peptides is most effective for the treatment of congestive heart failure, renal failure and cancer? Vesely DL, Clin Exp Pharmacol Physiol 2006 33 169 176 10.1111/j.1440-1681.2006.04344.x 16487258
2. Atrial natriuretic peptides: anticancer agents. Vesely DL, J Investig Med 2005 53 360 365 16297362 (Pubitemid 41814249)
3. An unsuspected metabolic role for atrial natriuretic peptides: the control of lipolysis, lipid mobilization, and systemic nonesterified fatty acids levels in humans. Lafontan M, Moro C, Sengenes C, Galitzky J, Crampes F, Berlan M, Arterioscler Thromb Vasc Biol 2005 25 2032 2042 10.1161/01.ATV.0000183728. 14712.d8 16123323 (Pubitemid 41416298)
4. Metabolic syndrome as a precursor of cardiovascular disease and type 2 diabetes mellitus. Wilson PW, D'Agostino RB, Parise H, Sullivan L, Meigs JB, Circulation 2005 112 3066 3072 10.1161/CIRCULATIONAHA.105.539528 16275870 (Pubitemid 43113437)
5. Prevalence and clinical implication of metabolic syndrome in chronic heart failure. Miura Y, Fukumoto Y, Shiba N, Miura T, Shimada K, Iwama Y, Circ J 2010 74 2612 2621 10.1253/circj.CJ-10-0677 20953060
6. The metabolic syndrome predicts incident congestive heart failure: a 20-year follow-up study of elderly Finns. Wang J, Sarnola K, Ruotsalainen S, Moilanen L, Lepistö P, Laakso M, Atherosclerosis 2010 210 237 242 10.1016/j.atherosclerosis.2009.10.042 19945701
7. Insulin resistance and risk of congestive heart failure. Ingelsson E, Sundström J, Arnlöv J, Zethelius B, Lind L, JAMA 2005 294 334 341 10.1001/jama.294.3.334 16030278 (Pubitemid 41043777)
8. Natriuretic peptides: linking heart and adipose tissue in obesity and related conditions-a systematic review. Beleigoli AM, Diniz MF, Ribeiro AL, Obes Rev 2009 10 617 626 10.1111/j.1467-789X.2009.00624.x 19563456
9. Association of plasma natriuretic peptide levels with metabolic risk factors in ambulatory individuals. Wang TJ, Larson MG, Keyes MJ, Levy D, Benjamin EJ, Vasan RS, Circulation 2007 115 1345 1353 10.1161/CIRCULATIONAHA. 106.655142 17339551 (Pubitemid 46648370)
10. 2009 focused update incorporated into the ACC/AHA, Guidelines for the Diagnosis and Management of Heart Failure in Adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines: developed in collaboration with the International Society for Heart and Lung Transplantation. Hunt SA, Abraham WT, Chin MH, Feldman AM, Francis GS, Ganiats TG, Circulation 2005 2009 119 391 e479
11. How to diagnose diastolic heart failure: a consensus statement on the diagnosis of heart failure with normal left ventricular ejection fraction by the Heart Failure and Echocardiography Associations of the European Society of Cardiology. Paulus WJ, Tschöpe C, Sanderson JE, Rusconi C, Flachskampf FA, Rademakers FE, Eur Heart J 2007 28 2539 2550 10.1093/eurheartj/ehm037 17428822 (Pubitemid 47614269)
12. Fasting long-acting natriuretic peptide correlates inversely with metabolic syndrome in kidney transplantation patients. Hsu BG, Shih MH, Yang YC, Ho GJ, Lee MC, Transplant Proc 2012 44 646 650 10.1016/j.transproceed.2011.11. 008 22483460
13. Fasting serum level of fatty-acid-binding protein 4 positively correlates with metabolic syndrome in patients with coronary artery disease. Hsu BG, Chen YC, Lee RP, Lee CC, Lee CJ, Wang JH, Circ J 2010 74 327 331 10.1253/circj.CJ-09- 0568 20009357
14. Fasting adiponectin is inversely correlated with metabolic syndrome in patients with coronary artery disease. Wang JH, Lee CJ, Lee CC, Chen YC, Lee RP, Hsu BG, Intern Med 2010 49 739 747 10.2169/internalmedicine.49.3093 20424363
15. Fasting serum fatty acid-binding protein 4 level positively correlates with metabolic syndrome in hemodialysis patients. Tsai JP, Liou HH, Liu HM, Lee CJ, Lee RP, Hsu BG, Arch Med Res 2010 41 536 540 10.1016/j.arcmed.2010.09.007 21167393
16. Increased subcutaneous fat accumulation has a protective role against subclinical atherosclerosis in asymptomatic subjects undergoing general health screening. Narumi H, Yoshida K, Hashimoto N, Umehara I, Funabashi N, Yoshida S, Int J Cardiol 2009 135 150 155 10.1016/j.ijcard.2008.03.044 18593641
17. Metabolic syndrome-a new world-wide definition. A consensus statement from the International Diabetes Federation. Alberti KG, Zimmet PZ, Shaw J, Diabet Med 2006 23 469 480 16681555
18. Definition, diagnosis and classification of diabetes mellitus and its complications. I. Diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Alberti KG, Zimmet PZ, Diabet Med 1998 15 539 553 10.1002/(SICI)1096-9136(199807)15:7<539::AID-DIA668>3.0.CO;2-S 9686693 (Pubitemid 28319935)
19. Cardiac endocrine function is an essential component of the homeostatic regulation network: physiological and clinical implications. Clerico A, Recchia FA, Passino C, Emdin M, Am J Physiol Heart Circ Physiol 2006 290 17 H29 16373590
20. Plasma levels and molecular forms of proatrial natriuretic peptides in healthy subjects and in patients with congestive heart failure. Azizi C, Maistre G, Kalotka H, Isnard R, Barthélemy C, Masson F, J Endocrinol 1996 148 51 57 10.1677/joe.0.1480051 8568471 (Pubitemid 26017033)
21. Metabolic syndrome increases mortality in heart failure. Tamariz L, Hassan B, Palacio A, Arcement L, Horswell R, Hebert K, Clin Cardiol 2009 32 327 331 10.1002/clc.20496 19569069
22. Renin-angiotensin system, natriuretic peptides, obesity, metabolic syndrome, and hypertension: an integrated view in humans. Wang S, Soni KG, Semache M, Casavant S, Fortier M, Pan L, J Hypertens 2008 26 831 843 10.1097/HJH.0b013e3282f624a0 18398321 (Pubitemid 351540757)
23. Control of lipolysis by natriuretic peptides and cyclic GMP. Lafontan M, Moro C, Berlan M, Crampes F, Sengenes C, Galitzky J, Trends Endocrinol Metab 2008 19 130 137 10.1016/j.tem.2007.11.006 18337116 (Pubitemid 351608304)
24. Lipolysis and the integrated physiology of lipid energy metabolism. Wang S, Soni KG, Semache M, Casavant S, Fortier M, Pan L, Mol Genet Metab 2008 95 117 126 10.1016/j.ymgme.2008.06.012 18762440
25. Natriuretic peptides and cardiovascular damage in the metabolic syndrome: molecular mechanisms and clinical implications. Savoia C, Volpe M, Alonzo A, Rossi C, Rubattu S, Clin Sci 2009 118 231 240 10.1042/CS20090204 19886866
26. Natriuretic peptides enhance the production of adiponectin in human adipocytes and in patients with chronic heart failure. Tsukamoto O, Fujita M, Kato M, Yamazaki S, Asano Y, Ogai A, J Am Coll Cardiol 2009 53 2070 2077 10.1016/j.jacc.2009.02.038 19477358
27. Natriuretic peptide metabolism, clearance and degradation. Potter LR, FEBS J 2011 278 1808 1817 10.1111/j.1742-4658.2011.08082.x 21375692
28. Dysregulation of pulsatility in aging IV. Pulsatile signaling and cardiovascular aging: functions and regulation of natriuretic peptide signaling. Charloux A, Brandenberger G, Piquard F, Geny B, Ageing Res Rev 2008 7 151 163 10.1016/j.arr.2007.12.001 18243818
29. Impact of obesity on plasma natriuretic peptide levels. Wang TJ, Larson MG, Levy D, Benjamin EJ, Leip EP, Wilson PW, Circulation 2004 109 594 600 10.1161/01.CIR.0000112582.16683.EA 14769680 (Pubitemid 38198866)
30. Determinants of N-terminal proatrial natriuretic peptide plasma levels in a survey of adult male population from Southern Italy. Rubattu S, Barbato A, Marchitti S, Iacone R, Di Castro S, Evangelista A, J Hypertens 2010 28 1638 1645 10.1097/HJH.0b013e32833a39aa 20453667
31. Expression and functional roles of guanylate cyclase isoforms in BRIN-BD11 β-cells. Russell MA, Morgan N, Islets 2010 2 23 31
32. Long-term treatment with atrial natriuretic peptide inhibits ATP production and insulin secretion in rat pancreatic islets. You H, Laychock SG, Am J Physiol Endocrinol Metab 2011 300 435 E444 10.1152/ajpendo.00398.2010 20959527
33. Cardiac remodeling in obesity. Abel ED, Litwin SE, Sweeney G, Physiol Rev 2008 88 389 419 10.1152/physrev.00017.2007 18391168 (Pubitemid 351520084)
34. Body composition and heart failure prevalence and prognosis: getting to the fat of the matter in the «obesity paradox» Lavie CJ, Milani RV, Ventura HO, Romero-Corral A, Mayo Clin Proc 2010 85 605 608 10.4065/mcp.2010. 0333 20592168
35. Metabolic syndrome and heart failure-the risk, paradox, and treatment. Gaddam KK, Ventura HO, Lavie CJ, Curr Hypertens Rep 2011 13 142 148 10.1007/s11906-011-0179-x 21298579
36. Augmentation of the cardiac natriuretic peptides by beta-receptor antagonism: evidence from a population-based study. Luchner A, Burnett JC Jr, Jougasaki M, Hense HW, Riegger GA, Schunkert H, J Am Coll Cardiol 1998 32 1839 1844 10.1016/S0735-1097(98)00478-1 9857860 (Pubitemid 29010443)
37. Early atorvastatin therapy improves cardiac function in patients with acute myocardial infarction. Teshima Y, Yufu K, Akioka H, Iwao T, Anan F, Nakagawa M, J Cardiol 2009 53 58 64 10.1016/j.jjcc.2008.08.008 19167639
38. The effects of the PPAR-gamma agonist pioglitazone on plasma concentrations of circulating vasoactive factors in type II diabetes mellitus. de Boer RA, Martens FM, Kuipers I, Boomsma F, Visseren FL, J Hum Hypertens 2010 24 74 76 10.1038/jhh.2009.84 19847195